🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 15 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/04/2023 18,35 18,47 17,62 17,89 -1,92% 4,63% 595.500
03/04/2023 18,18 18,51 17,76 18,24 +0,00% 4,13% 724.600
31/03/2023 17,55 18,51 17,55 18,24 +4,47% 5,47% 957.600
30/03/2023 18,05 18,18 17,01 17,46 -3,27% 6,46% 854.200
29/03/2023 17,90 18,13 17,57 18,05 +2,44% 3,13% 664.600
28/03/2023 17,50 17,69 17,42 17,62 -0,17% 1,54% 551.600
27/03/2023 17,70 18,17 17,49 17,65 +0,17% 3,84% 761.200
24/03/2023 16,28 17,80 15,93 17,62 +7,70% 11,49% 1.435.500
23/03/2023 16,16 16,59 16,00 16,36 +2,51% 3,65% 761.900
22/03/2023 16,82 16,82 15,93 15,96 -4,60% 5,29% 1.019.500
21/03/2023 16,49 16,97 16,23 16,73 +1,15% 4,46% 1.272.100
20/03/2023 16,38 16,69 16,26 16,54 +0,55% 2,63% 1.808.000
17/03/2023 16,83 16,94 16,10 16,45 -3,01% 4,99% 5.713.800
16/03/2023 16,81 17,19 16,38 16,96 +0,00% 4,82% 759.700
15/03/2023 16,76 17,22 16,63 16,96 -1,22% 3,52% 709.400
14/03/2023 17,51 17,77 16,85 17,17 +0,00% 5,25% 769.900
13/03/2023 16,57 17,58 16,57 17,17 +3,75% 6,10% 1.198.100
10/03/2023 16,51 16,60 15,70 16,55 -0,18% 5,45% 1.730.500
09/03/2023 17,71 17,98 16,48 16,58 -6,75% 8,47% 1.142.400
08/03/2023 17,65 17,81 17,44 17,78 +0,62% 2,10% 753.300
07/03/2023 17,79 18,49 17,62 17,67 -0,67% 4,92% 632.700
06/03/2023 18,26 18,26 17,45 17,79 -2,52% 4,44% 1.219.200
03/03/2023 17,89 18,42 17,76 18,25 +3,87% 3,69% 1.127.900
02/03/2023 17,35 17,76 17,28 17,57 +0,86% 2,72% 934.000
01/03/2023 18,44 18,88 17,26 17,42 -4,34% 8,79% 1.777.300
28/02/2023 18,10 18,37 17,85 18,21 +0,39% 2,85% 1.028.200
27/02/2023 18,71 18,71 18,11 18,14 -0,93% 3,21% 1.039.000
24/02/2023 18,40 18,73 18,13 18,31 -1,88% 3,26% 581.700
23/02/2023 19,16 19,28 18,17 18,66 -2,25% 5,79% 780.200
22/02/2023 18,50 19,25 18,41 19,09 +2,74% 4,54% 873.500